Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 763, Issue -, Pages 143-148Publisher
ELSEVIER
DOI: 10.1016/j.ejphar.2015.05.019
Keywords
G protein-coupled receptor; Signaling; Cardiac; Contractility; Therapeutic target
Categories
Ask authors/readers for more resources
G protein coupled receptors (GPCRs), such as beta-adrenergic and angiotensin II receptors, located in the membranes of all three major cardiac cell types, i.e. myocytes, fibroblasts and endothelial cells, play crucial roles in regulating cardiac function and morphology. Their importance in cardiac physiology and disease is reflected by the fact that, collectively, they represent the direct targets or over a third of the currently approved cardiovascular drugs used in clinical practice. Over the past few decades, advances in elucidation of their structure, function and the signaling pathways they elicit, specifically in the heart, have led to identification of an increasing number of new molecular targets for heart disease therapy. Here, we review these signaling modalities employed by GPCRs known to be expressed in the cardiac myocyte membranes and to directly modulate cardiac contractility. We also highlight drugs and drug classes that directly target these GPCRs to modulate cardiac function, as well as molecules involved in cardiac GPCR signaling that have the potential of becoming novel drug targets for modulation of cardiac function in the future. (C) 2015 Elsevier B.V. All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available